MCID: VLV034
MIFTS: 49

Vulva Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Vulva Squamous Cell Carcinoma

MalaCards integrated aliases for Vulva Squamous Cell Carcinoma:

Name: Vulva Squamous Cell Carcinoma 11 14
Squamous Cell Carcinoma of Vulva 11 71 33
Vulvar Squamous Cell Carcinoma 11 58 16
Squamous Cell Carcinoma of the Vulva 58
Vulvar Epidermoid Carcinoma 11

Characteristics:


Age Of Onset:

Vulvar Squamous Cell Carcinoma: Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:2101
NCIt 49 C4052
SNOMED-CT 68 254895003
Orphanet 58 ORPHA494448
ICD11 33 146824338
UMLS 71 C0280856

Summaries for Vulva Squamous Cell Carcinoma

Orphanet: 58 A rare vulvar carcinoma characterized by an ulcer, nodule, macule, or pedunculated mass which is histologically composed of infiltrating islands of malignant squamous cells. Histological subtypes include keratinizing, non-keratinizing, basaloid, warty, and verrucous carcinomas. Some tumors are associated with human papilloma virus, smoking, high grade squamous intraepithelial lesion, chronic vulvar inflammatory disorders, or differentiated vulvar intraepithelial neoplasia. Patients may present with discharge, bleeding, or pain. Most important prognostic features are tumor depth and lymph node status.

MalaCards based summary: Vulva Squamous Cell Carcinoma, also known as squamous cell carcinoma of vulva, is related to suppressor of tumorigenicity 3 and anogenital venereal wart. An important gene associated with Vulva Squamous Cell Carcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Malignant pleural mesothelioma and Gastrin signaling pathway. The drugs Pembrolizumab and Nivolumab have been mentioned in the context of this disorder. Affiliated tissues include epidermis of the vulvar tissue, lymph node and t cells, and related phenotype is no phenotypic analysis.

Disease Ontology: 11 A vulva carcinoma and has material basis in squamous cells and is located in the epidermis of the vulvar tissue.

Related Diseases for Vulva Squamous Cell Carcinoma

Diseases related to Vulva Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.8 TP53 CDKN2A
2 anogenital venereal wart 30.7 TP53 GP5 CDKN2A
3 basaloid squamous cell carcinoma 30.4 TP53 CDKN2A
4 mismatch repair cancer syndrome 30.3 TP53 PIK3CA CD274
5 skin melanoma 30.3 TP53 PIK3CA CDKN2A CD274
6 keratinizing squamous cell carcinoma 30.3 TP53 PIK3CA EGFR CDKN2A
7 cervical cancer 30.2 TP53 PIK3CA MIR31HG MEG3 MALAT1 CDKN2A
8 keratoacanthoma 30.1 TP53 PIK3CA EGFR
9 skin carcinoma 30.1 TP53 EGFR CDKN2A CD274
10 cervical squamous cell carcinoma 30.0 TP53 PIK3CA EGFR CDKN2A
11 vaginal cancer 30.0 TP53 GP5 EGFR CDKN2A CD274
12 squamous cell carcinoma 29.9 TP53 PIK3CA MALAT1 EGFR CDKN2A
13 uterine corpus cancer 29.9 TP53 PIK3CA EGFR CDKN2A CD274
14 verrucous carcinoma 29.9 TP53 PIK3CA GP5 EGFR CDKN2A
15 skin disease 29.8 TP53 PIK3CA MIR19B1 EGFR CDKN2A CD274
16 human papillomavirus infectious disease 29.5 TP53 PIK3CA MIR19B1 GP5 EGFR CDKN2A
17 vulvar disease 28.8 TP53 PRICKLE2-AS1 PIK3CA MIR590 MIR4712 MIR3147
18 vulva cancer 28.4 ZNF582 WEE1 TP53 PRICKLE2-AS1 PIK3CA MIR590
19 vulva verrucous carcinoma 11.3
20 vulvar basaloid squamous cell carcinoma 11.3
21 vulvar keratinizing squamous cell carcinoma 11.3
22 vulvar keratoacanthoma-like carcinoma 11.3
23 vulvar non-keratinizing squamous cell carcinoma 11.3
24 lichen sclerosus et atrophicus 10.8
25 papilloma 10.6
26 adenoid squamous cell carcinoma 10.4
27 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.4 TP53 CDKN2A
28 endometrial squamous cell carcinoma 10.4 TP53 CDKN2A
29 middle ear squamous cell carcinoma 10.3 GP5 CDKN2A
30 penis basal cell carcinoma 10.3 GP5 CDKN2A
31 bizarre leiomyoma 10.3 TP53 CDKN2A
32 cervical clear cell adenocarcinoma 10.3 GP5 CDKN2A
33 larynx squamous papilloma 10.3 TP53 CDKN2A
34 conjunctival squamous cell carcinoma 10.3 TP53 CDKN2A
35 bartholin's gland disease 10.3 MIR4712 MIR3147 MIR19B1
36 vaginal carcinosarcoma 10.3 TP53 PIK3CA
37 comedo carcinoma 10.3 TP53 GP5
38 thyroid cancer, nonmedullary, 1 10.3 TP53 MEG3 MALAT1
39 androgen insensitivity syndrome 10.3
40 cellulitis 10.3
41 fasciitis 10.3
42 necrotizing fasciitis 10.3
43 syndrome with 46,xy disorder of sex development 10.3
44 bladder clear cell adenocarcinoma 10.3 TP53 CDKN2A
45 atypical neurofibroma 10.3 TP53 CDKN2A
46 squamous cell papilloma 10.3 TP53 GP5 CDKN2A
47 malignant dermis tumor 10.3 MIR19B1 CD274
48 lip cancer 10.3 TP53 CDKN2A
49 vulvar melanoma 10.3 MIR19B1 CD274
50 malignant skin fibrous histiocytoma 10.3 MIR19B1 CD274

Graphical network of the top 20 diseases related to Vulva Squamous Cell Carcinoma:



Diseases related to Vulva Squamous Cell Carcinoma

Symptoms & Phenotypes for Vulva Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Vulva Squamous Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.17 CD274 CDKN2A EGFR MALAT1 PIK3CA PLXDC2

Drugs & Therapeutics for Vulva Squamous Cell Carcinoma

Drugs for Vulva Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
2
Nivolumab Approved Phase 2 946414-94-4
3
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
4
Avelumab Approved, Investigational Phase 1, Phase 2 1537032-82-8
5
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
6
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
7
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
8
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
9
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
10
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
11
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
12
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
13
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
14
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
15
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
16
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
17
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
19 Immune Checkpoint Inhibitors Phase 2
20 Vaccines Phase 1, Phase 2
21 Albumin-Bound Paclitaxel Phase 2
22 Antimitotic Agents Phase 2
23 Tubulin Modulators Phase 2
24 Vitamins Phase 1, Phase 2
25 Folate Phase 1, Phase 2
26 Vitamin B9 Phase 1, Phase 2
27 Trace Elements Phase 1, Phase 2
28 Vitamin B Complex Phase 1, Phase 2
29 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
30 Antidotes Phase 1, Phase 2
31 Pharmaceutical Solutions Phase 1, Phase 2
32 Hematinics Phase 1, Phase 2
33 Micronutrients Phase 1, Phase 2
34 Protective Agents Phase 1, Phase 2
35 Immunoglobulins, Intravenous Phase 2
36 Immunoglobulins Phase 2
37 Immunoglobulin G Phase 2
38 Antibodies, Monoclonal Phase 2
39 Antibodies Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 Immunologic Factors Phase 2
42 Angiogenesis Inhibitors Phase 2
43 Endothelial Growth Factors Phase 2
44 Mitogens Phase 2
45 Antimetabolites Phase 2
46 Immunosuppressive Agents Phase 2
47 Antiviral Agents Phase 1, Phase 2
48 Anti-Retroviral Agents Phase 1, Phase 2
49 Anti-Infective Agents Phase 1, Phase 2
50 Anti-HIV Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes Completed NCT00898352 Phase 3
2 A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva Completed NCT00068406 Phase 2 Cisplatin
3 A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma Recruiting NCT04430699 Phase 2 Cisplatin;Pembrolizumab
4 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
5 A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies. Recruiting NCT03260023 Phase 1, Phase 2 Avelumab
6 Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) Recruiting NCT04192253 Phase 2 Paclitaxel and Carboplatin
7 Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT) Recruiting NCT04161664 Phase 2 Paclitaxel and Carboplatin
8 A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib
9 A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab
10 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) Active, not recruiting NCT01595061 Phase 2 Cisplatin;Gemcitabine Hydrochloride
11 A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers Not yet recruiting NCT05639972 Phase 1, Phase 2 Conditioning, E7 TCR-T cells, and aldesleukin
12 Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer Active, not recruiting NCT03452332 Phase 1
13 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
14 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
15 Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Recruiting NCT03987555
16 GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study Active, not recruiting NCT01500512
17 STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision: STRIVE Study Not yet recruiting NCT05576831
18 A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters (DaRT) for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Not yet recruiting NCT04761146

Search NIH Clinical Center for Vulva Squamous Cell Carcinoma

Genetic Tests for Vulva Squamous Cell Carcinoma

Anatomical Context for Vulva Squamous Cell Carcinoma

Organs/tissues related to Vulva Squamous Cell Carcinoma:

FMA: Epidermis Of The Vulvar Tissue
MalaCards : Lymph Node, T Cells, Skin, Endothelial, Smooth Muscle, Lung, Breast

Publications for Vulva Squamous Cell Carcinoma

Articles related to Vulva Squamous Cell Carcinoma:

(show top 50) (show all 974)
# Title Authors PMID Year
1
Differential proteomic expression in indolent vulvar lichen sclerosus, transforming vulvar lichen sclerosus and normal vulvar tissue. 62
35960231 2022
2
Molecular Analysis of HPV-independent Primary Endometrial Squamous Cell Carcinoma Reveals TP53 and CDKN2A Comutations : A Clinicopathologic Analysis With Re-evaluation of Diagnostic Criteria. 62
36069815 2022
3
Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy. 62
36281250 2022
4
Guideline-Discordant Care in Early-Stage Vulvar Cancer. 62
36357957 2022
5
Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018. 62
35969832 2022
6
Can late lymphoscintigraphy be omitted in the sentinel node procedure in early-stage vulvar cancer? 62
36412099 2022
7
Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis. 62
36409332 2022
8
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience. 62
34289750 2022
9
Fertility-sparing treatment of locally advanced vulvar squamous cell carcinoma in a young patient. 62
36158735 2022
10
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. 62
36085090 2022
11
HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva. 62
35437330 2022
12
N6-methyladenosine RNA modification (m6A) is of prognostic value in HPV-dependent vulvar squamous cell carcinoma. 62
36050747 2022
13
Significance of p53 and presence of differentiated vulvar intra-epithelial neoplasia (dVIN) at resection margin in early stage human papillomavirus-independent vulvar squamous cell carcinoma. 62
36100281 2022
14
Cellulitis and bacteraemia caused by Streptococcus dysgalactiae post radical vulvectomy and bilateral inguinal lymph node dissection for FIGO IB squamous cell carcinoma of the vulva, a case report. 62
35985116 2022
15
Time to completion of radiation treatment in locally advanced squamous cell carcinoma of the vulva and the impact on survival. 62
36154760 2022
16
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis. 62
36150913 2022
17
Necrotizing fasciitis arising from squamous cell carcinoma of the vulva. 62
36199909 2022
18
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. 62
35361487 2022
19
Nicotinamide N-methyltransferase expression in squamous cell carcinoma of the vulva. 62
35499473 2022
20
HPV-independent and HPV-associated vulvar squamous cell carcinoma: two different cancers. 62
35914776 2022
21
Tumor budding activity is an independent prognostic factor in squamous cell carcinoma of the vulva. 62
35594936 2022
22
Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical technique. 62
35764349 2022
23
Female Genital Schistosomiasis (FGS) Associated with Well-Differentiated Squamous Cell Carcinoma of the Vulva: A Case Report. 62
36062964 2022
24
Vulvar squamous cell carcinoma metastasizes to lung pleura. 62
35788112 2022
25
Prognostic role of perineural invasion in vulvar squamous cell carcinoma: A systematic review and meta-analysis. 62
35811178 2022
26
Prognostic nomograms to predict overall survival and cause specific death in vulvar squamous cell carcinoma. 62
35428690 2022
27
Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines. 62
35496740 2022
28
Epithelial-mesenchymal transition (EMT) in vulvar cancer with and without inguinal lymph node involvement. 62
34495397 2022
29
Autologous lipoaspirate as a new treatment of vulvar lichen sclerosus: A review on literature. 62
35276020 2022
30
Vulvar Squamous Cell Carcinoma With Sarcomatoid Features are HPV-independent Lesions: A Subset are Also Associated With TP53-independent Lesions and Radiation Therapy. 62
35639348 2022
31
Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct. 62
34756880 2022
32
CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. 62
33692092 2022
33
Immunohistochemical expression of ErbB/HER family proteins in patients with vulvar cancer. 62
34270807 2022
34
Low incidence of pulmonary metastases in vulvar cancer patients: limited value of routine chest imaging based on a cohort study. 62
33342026 2022
35
Sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma: a proposed protocol for a multicentre observational study. 62
35461213 2022
36
Development and validation of nomograms predicting cancer-specific survival of vulvar cancer patients: based on the Surveillance, Epidemiology, and End Results Program. 62
33899929 2022
37
Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States. 62
35031190 2022
38
Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma. 62
34973843 2022
39
An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. 62
34910394 2022
40
The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia. 62
33782343 2022
41
Squamous Cell Carcinoma of the Vulva: A Survival and Epidemiologic Study with Focus on Surgery and Radiotherapy. 62
35207308 2022
42
Forty-eight-year-old female MUTYH carrier presenting with five concurrent primary cancers. 62
34173730 2022
43
Risk of Vulvar Squamous Cell Carcinoma in Lichen Sclerosus and Lichen Planus: A Systematic Review. 62
34678521 2022
44
The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva. 62
34893347 2022
45
High-risk human papillomavirus-associated vulvar neoplasia among women living with human immunodeficiency virus in Zambia. 62
35747556 2022
46
[Vulvar intraepithelial neoplasias]. 62
33744030 2022
47
Biventricular cardiac metastasis from vulvar squamous cell carcinoma. 62
35813496 2022
48
Analysis of Short-Term Efficacy of Gasless Single-Port Laparoscopic Inguinal Lymphadenectomy Through Vulva Incision for Vulvar Cancer. 62
35402502 2022
49
Case Report: Inguinal Myxofibrosarcoma Arising From the Surgical Site of Resected Squamous Cell Carcinoma. 62
35600384 2022
50
Vulvar Squamous-Cell Carcinoma. 62
34995026 2022

Variations for Vulva Squamous Cell Carcinoma

Cosmic variations for Vulva Squamous Cell Carcinoma:

8 (show top 50) (show all 1309)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM122736660 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.59C>T p.P20L 17:7675157-7675157 15
2 COSM93191413 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.482C>T p.A161V 17:7675130-7675130 15
3 COSM87899887 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 15
4 COSM142560375 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.736G>A p.E246K 17:7673767-7673767 15
5 COSM105620380 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.782+414G>A p.? 17:7673767-7673767 15
6 COSM144013457 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.820G>A p.E274K 17:7673767-7673767 15
7 COSM144013161 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.557T>G p.V186G 17:7674941-7674941 15
8 COSM144290515 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.637G>C p.E213Q 17:7674861-7674861 15
9 COSM112255951 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.455C>T p.P152L 17:7675157-7675157 15
10 COSM144309944 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.407G>A p.R136H 17:7675088-7675088 15
11 COSM111878732 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 15
12 COSM122738565 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.250G>A p.V84M 17:7674885-7674885 15
13 COSM122735959 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.*43C>T p.? 17:7670685-7670685 15
14 COSM93183307 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 15
15 COSM144087106 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 15
16 COSM145020119 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.497A>G p.Y166C 17:7674917-7674917 15
17 COSM105620358 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 15
18 COSM144013367 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.710G>A p.R237Q 17:7674220-7674220 15
19 COSM112309251 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.339C>G p.F113L 17:7676030-7676030 15
20 COSM143157028 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.340C>T p.R114C 17:7673803-7673803 15
21 COSM144366627 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.415C>T p.H139Y 17:7675080-7675080 15
22 COSM143389578 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.397G>A p.V133I 17:7675098-7675098 15
23 COSM111758876 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 15
24 COSM111761580 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.455C>T p.P152L 17:7675157-7675157 15
25 COSM142837563 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 15
26 COSM122734046 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.263A>G p.Y88C 17:7674872-7674872 15
27 COSM122792873 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.306C>A p.Y102* 17:7674261-7674261 15
28 COSM87898723 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 15
29 COSM87898424 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.722C>T p.S241F 17:7674241-7674241 15
30 COSM142561357 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.452C>T p.P151L 17:7674962-7674962 15
31 COSM145019215 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7673764-7673764 15
32 COSM143943797 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 15
33 COSM122271635 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.55C>T p.P19S 17:7675161-7675161 15
34 COSM143156843 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 15
35 COSM144311333 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.726C>G p.D242E 17:7673777-7673777 15
36 COSM143409179 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.876+1G>C p.? 17:7673534-7673534 15
37 COSM122734486 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.520C>T p.R174* 17:7673704-7673704 15
38 COSM93239606 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 15
39 COSM106053265 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.853G>A p.E285K 17:7673767-7673767 15
40 COSM106053452 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 15
41 COSM144016191 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.422C>T p.P141L 17:7675157-7675157 15
42 COSM112292789 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.993+1G>C p.? 17:7673534-7673534 15
43 COSM112578970 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.670G>C p.E224Q 17:7674861-7674861 15
44 COSM122288931 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.132C>A p.C44* 17:7675084-7675084 15
45 COSM144345858 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.751C>T p.R251C 17:7673752-7673752 15
46 COSM144310279 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.736G>A p.E246K 17:7673767-7673767 15
47 COSM143370575 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.701G>A p.R234H 17:7673802-7673802 15
48 COSM111758637 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 15
49 COSM142837558 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 15
50 COSM93229231 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.868C>T p.R290C 17:7673752-7673752 15

Expression for Vulva Squamous Cell Carcinoma

Search GEO for disease gene expression data for Vulva Squamous Cell Carcinoma.

Pathways for Vulva Squamous Cell Carcinoma

GO Terms for Vulva Squamous Cell Carcinoma

Biological processes related to Vulva Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of miRNA maturation GO:1903800 8.62 TP53 EGFR

Sources for Vulva Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....